Trials / Completed
CompletedNCT06359821
Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer
A Study to Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry of ZA-001, an Alpha-particle-emitting (At211) Radiopharmaceutical, in Metastatic Castration Resistant Prostate Cancer
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- Male
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
A Study to Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry of ZA-001, an Alpha-particle-emitting (At211) Radiopharmaceutical, in metastatic castration resistant prostate cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZA-001 | Study drug ZA-001 administered via intravenous injection. |
Timeline
- Start date
- 2024-05-17
- Primary completion
- 2024-10-14
- Completion
- 2024-10-14
- First posted
- 2024-04-11
- Last updated
- 2025-02-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06359821. Inclusion in this directory is not an endorsement.